scholarly journals microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer

Tumor Biology ◽  
2018 ◽  
Vol 40 (5) ◽  
pp. 101042831877586 ◽  
Author(s):  
Ahmed Hussein Zedan ◽  
Torben Frøstrup Hansen ◽  
Jannie Assenholt ◽  
Mindaugas Pleckaitis ◽  
Jonna Skov Madsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Plasma Level ◽  
Advanced Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Locally Advanced ◽  
Tumour Tissue ◽  
Newly Diagnosed ◽  
Locally Advanced Prostate Cancer ◽  
Mirna 93 ◽  
Benign Prostate

Prostate cancer is the most common cancer among men in the western world. Clinical practice is continuously challenged by the pitfalls of the available diagnostic tools. microRNAs may represent promising biomarkers in many types of human cancers, including prostate cancer. The aim of this study was to investigate microRNA expression in tumour tissue and matched plasma in a cohort of patients with primary metastatic prostate cancer. The relative expression of 12 microRNAs was assessed in diagnostic needle biopsies from the prostate and matched plasma samples in two prospective cohorts (screening cohorts) comprising 21 patients with metastatic prostate cancer and 25 control patients. An independent validation cohort of plasma samples was collected prospectively from 149 newly diagnosed patients with local/locally advanced prostate cancer. Analyses were performed using real-time polymerase chain reaction. miRNA-93 showed a significant negative correlation between expression in tumour tissue and plasma in patients with metastatic prostate cancer. Furthermore, the plasma level of miRNA-93 significantly decreased after treatment in patients with local/locally advanced prostate cancer compared to baseline plasma level. The expression of six microRNAs (let-7b, miRNA-34a, -125b, -143, -145 and -221) was downregulated, and three microRNAs (miRNA-21, -25 and miRNA-93) were upregulated in tumour tissue compared to benign prostate tissue. In plasma, six microRNAs were upregulated (miRNA-21, -125b, -126, -141, -143 and -375), while let-7b was downregulated in patients with metastatic prostate cancer compared to the control cohort. In the metastatic prostate cancer cohort, the expression of four microRNAs (miRNA-125b, -126, -143 and -221), and miRNA-141 in tissue was associated with Gleason score and prostate-specific antigen, respectively. The expression of miRNA-93 in tumour tissue was correlated with matched plasma levels and showed a significant decrease in plasma level after intervention in local prostate cancer. Differential expression between tumour and benign prostate was detected for several microRNAs in both tissue and plasma.

scholarly journals rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy

2019 ◽  
Vol 20 (9) ◽  
pp. 2082
Author(s):  
Chiara Zanusso ◽  
Eva Dreussi ◽  
Roberto Bortolus ◽  
Chiara Romualdi ◽  
Sara Gagno ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immune System ◽  
Biochemical Recurrence ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Significant Snps ◽  
P Value ◽  
Training Set ◽  
Locally Advanced Prostate Cancer ◽  
New Biomarkers

Up to 30–50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization of PCa patients’ treatment. The aim of this study is to define the immunogenetic biomarkers of 10 year BCR (primary aim), 10 year overall survival (OS) and 5 year BCR (secondary aims). In this mono-institutional retrospective study, 549 Caucasian patients (a discovery set n = 418; a replication set n = 131) were affected by locally advanced PCa and homogeneously treated with RT. In the training set, associations were made between 447 SNPs in 77 genes of the immune system; and 10 year BCR and 10 year OS were tested through a multivariate Cox proportional hazard model. Significant SNPs (p-value < 0.05, q-value < 0.15) were analyzed in the replication set. Replicated SNPs were tested for 5 year BCR in both sets of patients. A polymorphism in the PDL1 gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: p = 0.003, HR (95% CI) = 0.58 (0.41–0.83); replication set: p = 0.063, HR (95% CI) = 0.52 (0.26–1.04)) that was significantly associated with 5 year BCR (training set: p = 0.009, HR (95% CI) = 0.59 (0.40–0.88); replication set: p = 0.036, HR (95% CI) = 0.39 (0.16–0.94)). No biomarkers of OS were replicated. rs4143815-PDL1 arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa.

Anatomically robust proton therapy using multiple planning computed tomography scans for locally advanced prostate cancer

2021 ◽  
Vol 60 (5) ◽  
pp. 598-604
Author(s):  
Kia Busch ◽  
Benjamin Dahl ◽  
Stine E. Petersen ◽  
Heidi S. Rønde ◽  
Lise Bentzen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Proton Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Locally Advanced Prostate Cancer ◽  
Computed Tomography Scans
Sign in / Sign up

Export Citation Format

Share Document